Archive
527 articles, sorted by publication time.
Beyond anti-amyloid drugs, neuroinflammation and synaptic protection pathways are still seeking a clinical foothold; whether Vaccinex’s new data can support a larger trial will depend not only on whether the signal looks strong, but also on whether patient selection and endpoint design are sufficiently clear.
PinPoint’s machine-learning blood test is beginning to enter some NHS hospitals to help triage suspected gynecological cancer referrals; it may reduce invasive tests for low-risk women, but clinical trust will still depend on real-world performance, regulatory boundaries, and how doctors use the results.
Oncodaily’s report on Harpreet Singh reminds the market that beyond the pursuit of new therapies and platform technologies, what often truly determines whether a drug candidate can go the distance is the less flashy but critical work of trial design, evidence pathways, and regulatory communication.
In allogeneic hematopoietic stem cell transplantation, life-saving immune reconstitution often goes hand in hand with graft-versus-host disease; TREGZI’s approval makes cell engineering to regulate immune responses a formal option for the first time in adult hematologic malignancy transplantation in the United States.
Cytomegalovirus vaccines have long lacked an available product; the significance of this new data lies not in how novel the AI itself is, but in whether it can turn antigen selection into experimentally verifiable clues of immune protection.
A preclinical study brings a common sports supplement into a central question in tumor immunology: if dendritic cells can be supplied with enough energy, can killer T cells more powerfully recognize and attack cancer cells? The answer remains before human trials.
The life sciences cluster around Hyderabad supports India’s vast pharmaceutical production capacity and carries the image of a “pharma capital.” But when output figures are disproportionate to employment, fiscal returns, and local innovation gains, the issue is not only investment promotion results, but how a biopharma park turns scale into public value.
An expansion of a licensing partnership reflects a renewed adjustment in the division of roles between multinational drugmakers and Chinese domestic companies in the respiratory disease market; but with limited public information available, the clinical and commercial significance of the transaction can still only be interpreted cautiously.
A recovery demand brings drug price ceilings out of regulatory text and back onto patients’ bills: in India’s highly price-sensitive pharmaceutical market, compliance risk for multinational drugmakers is not only about fines, but also about trust in access to essential medicines.
As capital markets become increasingly selective about biotech risk, a large financing has brought respiratory disease R&D back into the spotlight; but beyond the size of the funding, the real test remains whether early science can be advanced into verifiable clinical evidence.
A 2026 R&D pipeline report has pushed spasticity treatment back into industry view; although candidate drugs remain limited, they show that pharmaceutical companies are trying to find more refined answers than existing muscle relaxants and botulinum toxin, balancing efficacy, dosing convenience, and long-term safety.
MEDIPOST’s CARTISTEM has enrolled and treated the first participant in a U.S. Phase 3 trial, moving a knee cartilage repair therapy that has been used in South Korea for many years into more rigorous cross-market clinical testing.